These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 16496381)
1. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Sui M; Chen F; Chen Z; Fan W Int J Cancer; 2006 Aug; 119(3):712-7. PubMed ID: 16496381 [TBL] [Abstract][Full Text] [Related]
2. Dexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice. Hou WJ; Guan JH; Dong Q; Han YH; Zhang R Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2902-8. PubMed ID: 24254559 [TBL] [Abstract][Full Text] [Related]
3. Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Pang D; Kocherginsky M; Krausz T; Kim SY; Conzen SD Cancer Biol Ther; 2006 Aug; 5(8):933-40. PubMed ID: 16775428 [TBL] [Abstract][Full Text] [Related]
4. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model. Kang HJ; Lee SH; Price JE; Kim LS Breast J; 2009; 15(3):223-9. PubMed ID: 19645775 [TBL] [Abstract][Full Text] [Related]
5. Glucocorticoids selectively inhibit paclitaxel-induced apoptosis: mechanisms and its clinical impact. Fan W; Sui M; Huang Y Curr Med Chem; 2004 Feb; 11(4):403-11. PubMed ID: 14965221 [TBL] [Abstract][Full Text] [Related]
6. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting. Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469 [TBL] [Abstract][Full Text] [Related]
7. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Aggarwal BB; Shishodia S; Takada Y; Banerjee S; Newman RA; Bueso-Ramos CE; Price JE Clin Cancer Res; 2005 Oct; 11(20):7490-8. PubMed ID: 16243823 [TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors. Chang J; Sui M; Fan W Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518 [TBL] [Abstract][Full Text] [Related]
9. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869 [TBL] [Abstract][Full Text] [Related]
10. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591 [TBL] [Abstract][Full Text] [Related]
11. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. Liao Y; Zou YY; Xia WY; Hung MC Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313 [TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876 [TBL] [Abstract][Full Text] [Related]
13. [Technetium-99m labeled synaptotagmin I C2A detection of paclitaxel-induced apoptosis in non-small cell lung cancer]. Wang F; Fang W; Ji SD; Meng QL; Li Y; Fan KW; Wang ZZ Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):351-4. PubMed ID: 17892130 [TBL] [Abstract][Full Text] [Related]
14. Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug. Brunetti J; Pillozzi S; Falciani C; Depau L; Tenori E; Scali S; Lozzi L; Pini A; Arcangeli A; Menichetti S; Bracci L Sci Rep; 2015 Dec; 5():17736. PubMed ID: 26626158 [TBL] [Abstract][Full Text] [Related]
15. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells. Chen YX; Wang Y; Fu CC; Diao F; Song LN; Li ZB; Yang R; Lu J Endocr Relat Cancer; 2010 Mar; 17(1):39-50. PubMed ID: 19776289 [TBL] [Abstract][Full Text] [Related]
16. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells. Tong L; Chen W; Wu J; Li H Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314 [TBL] [Abstract][Full Text] [Related]
17. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer. Bu H; He X; Zhang Z; Yin Q; Yu H; Li Y Int J Pharm; 2014 Aug; 471(1-2):206-13. PubMed ID: 24866272 [TBL] [Abstract][Full Text] [Related]
18. Time course of Paclitaxel-induced apoptosis in an experimental model of virus-induced breast cancer. Erba PA; Manfredi C; Lazzeri E; Minichilli F; Pauwels EK; Sbrana A; Strauss HW; Mariani G J Nucl Med; 2010 May; 51(5):775-81. PubMed ID: 20395330 [TBL] [Abstract][Full Text] [Related]
19. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Lee SJ; Ghosh SC; Han HD; Stone RL; Bottsford-Miller J; Shen DY; Auzenne EJ; Lopez-Araujo A; Lu C; Nishimura M; Pecot CV; Zand B; Thanapprapasr D; Jennings NB; Kang Y; Huang J; Hu W; Klostergaard J; Sood AK Clin Cancer Res; 2012 Aug; 18(15):4114-21. PubMed ID: 22693353 [TBL] [Abstract][Full Text] [Related]
20. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]